These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 12648471)

  • 21. Receptor-targeted cancer therapy.
    Richter M; Zhang H
    DNA Cell Biol; 2005 May; 24(5):271-82. PubMed ID: 15869404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting HER1/EGFR: a molecular approach to cancer therapy.
    Arteaga C
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
    Mendelsohn J; Baselga J
    J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic targeting of the epidermal growth factor receptor in human cancer.
    Dhomen NS; Mariadason J; Tebbutt N; Scott AM
    Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Tyrosine kinase: implications in tumor pathology and therapeutic perspectives].
    Peyrade F; Taillan B; Lebrun C; Baron V; Dujardin P
    Rev Med Interne; 1998 May; 19(5):366-72. PubMed ID: 9775178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Targeting epidermal growth factor receptor in cancer of the breast].
    Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
    Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence.
    Quatrale AE; Petriella D; Porcelli L; Tommasi S; Silvestris N; Colucci G; Angelo A; Azzariti A
    Front Biosci (Landmark Ed); 2011 Jan; 16(5):1973-85. PubMed ID: 21196277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
    Lage A; Crombet T; González G
    Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
    Ettinger DS
    Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
    Mitchell RA; Luwor RB; Burgess AW
    Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
    O'dwyer PJ; Benson AB
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):10-7. PubMed ID: 12422309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor as a therapeutic target for the treatment of colorectal cancer.
    Amador ML; Hidalgo M
    Clin Colorectal Cancer; 2004 May; 4(1):51-62. PubMed ID: 15207021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
    Janmaat ML; Giaccone G
    Oncologist; 2003; 8(6):576-86. PubMed ID: 14657536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
    Dancey JE; Schoenfeldt M
    Oncology (Williston Park); 2001 Jun; 15(6):748-50, 756-8. PubMed ID: 11430207
    [No Abstract]   [Full Text] [Related]  

  • 39. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
    Fry DW
    Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
    Pomerantz RG; Grandis JR
    Semin Oncol; 2004 Dec; 31(6):734-43. PubMed ID: 15599851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.